PARAMOUNT trial

China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, January 14, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Lung cancer, Clinical medicine, Medicine, Non-small-cell lung carcinoma, Small-cell carcinoma, Cancer, Treatment of lung cancer, PARAMOUNT trial, Non-Small Cell Lung Cancer, Tislelizumab, Tislelizumab Clinical Program, BeiGene

This is the third approval in China for tislelizumab, and its first in a lung cancer indication.

Key Points: 
  • This is the third approval in China for tislelizumab, and its first in a lung cancer indication.
  • Tislelizumab is being investigated in a broad clinical program, including five Phase 3 trials in lung cancer indications.
  • We are grateful to have a new treatment available in the front-line setting for patients with advanced squamous non-small cell lung cancer, said Jie Wang, M.D., Ph.D., National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.
  • The China National Medical Products Administration (NMPA) has granted tislelizumab full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy.

Europe Basal Cell Carcinoma Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 30, 2020
Health, General Health, Neoplasms, RTT, Cancer, Carcinoma, Clinical medicine, Lung cancer, Basal-cell carcinoma, Histopathology, PARAMOUNT trial, Skin cancer

The "Europe Basal Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Basal Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Basal Cell Carcinoma Market and Competitive Landscape - 2020, provides comprehensive insights into the Basal Cell Carcinoma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following:
    Basal Cell Carcinoma treatment options, Basal Cell Carcinoma late stage clinical trials pipeline, Basal Cell Carcinoma prevalence by countries, Basal Cell Carcinoma market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Basal Cell Carcinoma pipeline: Find out drugs in clinical trials for the treatment of Basal Cell Carcinoma by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Basal Cell Carcinoma drugs: Identify key drugs marketed and prescribed for Basal Cell Carcinoma in the US, including trade name, molecule name, and company
    Basal Cell Carcinoma drugs sales: Find out the sales value for Basal Cell Carcinoma drugs by countries
    Basal Cell Carcinoma market valuations: Find out the market size for Basal Cell Carcinoma drugs in 2019 by countries.

Europe Squamous Cell Carcinoma Market and Competitive Landscape 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, and Market Shares 2016-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 28, 2020
Pharmaceutical, Health, Oncology, Neoplasms, Cancer, Lung cancer, Clinical medicine, Anatomical pathology, RTT, Carcinoma, Squamous cell carcinoma, Head and neck cancer, PARAMOUNT trial

The "Europe Squamous Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Squamous Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The research report Europe Squamous Cell Carcinoma Market and Competitive Landscape - 2020, provides comprehensive insights into the Squamous Cell Carcinoma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Squamous Cell Carcinoma market size and drug sales.
  • Squamous Cell Carcinoma pipeline: Find out drugs in clinical trials for the treatment of Squamous Cell Carcinoma by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Squamous Cell Carcinoma drugs: Identify key drugs marketed and prescribed for Squamous Cell Carcinoma in the US, including trade name, molecule name, and company
    Squamous Cell Carcinoma drugs sales: Find out the sales value for Squamous Cell Carcinoma drugs by countries
    Squamous Cell Carcinoma market valuations: Find out the market size for Squamous Cell Carcinoma drugs in 2019 by countries.

Global Squamous Cell Carcinoma Market Insights, 2016-2024 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 17, 2020
Health, Oncology, Neoplasms, Cancer, Lung cancer, Clinical medicine, Anatomical pathology, RTT, Epithelium, Squamous cell carcinoma, Carcinoma, PARAMOUNT trial, Skin cancer

The "Global Squamous Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Squamous Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Squamous Cell Carcinoma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • The report covers the following: Squamous Cell Carcinoma treatment options, Squamous Cell Carcinoma late stage clinical trials pipeline, Squamous Cell Carcinoma prevalence by countries, Squamous Cell Carcinoma market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Squamous Cell Carcinoma pipeline: Find out drugs in clinical trials for the treatment of Squamous Cell Carcinoma by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Squamous Cell Carcinoma drugs: Identify key drugs marketed and prescribed for Squamous Cell Carcinoma in the US, including trade name, molecule name, and company
    Squamous Cell Carcinoma drugs sales: Find out the sales value for Squamous Cell Carcinoma drugs by countries
    Squamous Cell Carcinoma market valuations: Find out the market size for Squamous Cell Carcinoma drugs in 2019 by countries.

Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020

Retrieved on: 
Thursday, May 14, 2020
Lung cancer, Cancer, Clinical medicine, Neoplasms, Pemetrexed, Non-small-cell lung carcinoma, Small-cell carcinoma, Oncology, Cancer immunotherapy, PARAMOUNT trial, Treatment of lung cancer

The ASCO publication details are:

Key Points: 
  • The ASCO publication details are:
    Title: Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients.
  • Results: Fourteen (14) patients were enrolled across 6 dosing cohorts in the study.
  • Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy.
  • The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies.

BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis

Retrieved on: 
Tuesday, January 21, 2020
Clinical medicine, Chemical compounds, Cancer, Non-small-cell lung carcinoma, Lung cancer, Treatment of lung cancer, PARAMOUNT trial

Based on the pre-planned interim analysis, both tislelizumab treatment arms crossed the pre-specified efficacy boundary compared to chemotherapy alone.

Key Points: 
  • Based on the pre-planned interim analysis, both tislelizumab treatment arms crossed the pre-specified efficacy boundary compared to chemotherapy alone.
  • We are extremely excited about the compelling results that tislelizumab demonstrated in this Phase 3 trial and for its potential use as a first-line treatment for patients in China with advanced squamous NSCLC.
  • We look forward to continuing the development program for tislelizumab in lung cancer, which includes three other Phase 3 trials, and reporting additional data.
  • BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.

Investigator-initiated Phase II Clinical Study of Remetinostat Started in Patients With Squamous Cell Carcinoma

Retrieved on: 
Wednesday, December 18, 2019
Neoplasms, Cancer, Health, Carcinoma, RTT, Oncology, Lung cancer, Basal-cell carcinoma, Histopathology, Squamous cell carcinoma, PARAMOUNT trial, Squamous cell skin cancer

STOCKHOLM, Dec. 18, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)today announces that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC).

Key Points: 
  • STOCKHOLM, Dec. 18, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)today announces that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC).
  • Medivir is providing remetinostat drug supply for this study, and has full access to, and the rights to use, all clinical data after the study is complete.
  • "This study together with the ongoing study in basal cell carcinoma explore the potential of remetinostat to be used in multiple conditions beyond cutaneous T-cell lymphoma," said Dr. Uli Hacksell, CEO of Medivir.
  • The effect of remetinostat on basal cell carcinoma is investigated in an ongoing phase II study.

Global Basal Cell Carcinoma Market and Competitive Landscape Report 2018

Retrieved on: 
Monday, November 5, 2018
Cancer, Carcinoma, RTT, Basal-cell carcinoma, Histopathology, Lung cancer, PARAMOUNT trial

The "Global Basal Cell Carcinoma Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Basal Cell Carcinoma Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Basal Cell Carcinoma Market and Competitive Landscape - 2018, provides comprehensive insights into Basal Cell Carcinoma pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • The research is classified into following sections - Basal Cell Carcinoma overview with definitions, symptoms, etiology, diagnosis, treatment options; Basal Cell Carcinoma pipeline insights covering late stage clinical trials pipeline; Basal Cell Carcinoma prevalence trends by countries; Basal Cell Carcinoma market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Basal Cell Carcinoma pipeline: Find out the drugs in clinical trials for Basal Cell Carcinoma by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Basal Cell Carcinoma epidemiology: Find out the prevalence of Basal Cell Carcinoma by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2023
    Basal Cell Carcinoma products: Identify key products marketed and prescribed for Basal Cell Carcinoma by brand name, by molecule, by company, by branded / generic, by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Basal Cell Carcinoma market size: Find out the market size for Basal Cell Carcinoma drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2014
    Basal Cell Carcinoma drug sales: Find out the sales of Basal Cell Carcinoma drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan, Global
    Basal Cell Carcinoma drugs sales forecast: Sales forecast for Basal Cell Carcinoma drugs to 2023 by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Basal Cell Carcinoma market share analysis: Find out the market shares of Basal Cell Carcinoma drugs and outlook by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Did you know that we also offer Custom Research?

Global Squamous Cell Carcinoma Market and Competitive Landscape 2018: Pipeline, Epidemiology, Market Valuations, Product Sales, Market Forecast, Product Forecasts, and Market Shares 2014-2023

Retrieved on: 
Monday, October 29, 2018
Health, Medicine, Cancer, Epithelium, Oncology, Squamous cell carcinoma, Lung cancer, PARAMOUNT trial, International Cancer Genome Consortium

The "Global Squamous Cell Carcinoma Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Squamous Cell Carcinoma Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Squamous Cell Carcinoma Market and Competitive Landscape - 2018, provides comprehensive insights into Squamous Cell Carcinoma pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • The research is classified into following sections - Squamous Cell Carcinoma overview with definitions, symptoms, etiology, diagnosis, treatment options; Squamous Cell Carcinoma pipeline insights covering late stage clinical trials pipeline; Squamous Cell Carcinoma prevalence trends by countries; Squamous Cell Carcinoma market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Squamous Cell Carcinoma pipeline: Find out the drugs in clinical trials for Squamous Cell Carcinoma by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Squamous Cell Carcinoma epidemiology: Find out the prevalence of Squamous Cell Carcinoma by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2023
    Squamous Cell Carcinoma products: Identify key products marketed and prescribed for Squamous Cell Carcinoma by brand name, by molecule, by company, by branded / generic, by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Squamous Cell Carcinoma market size: Find out the market size for Squamous Cell Carcinoma drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2014
    Squamous Cell Carcinoma drug sales: Find out the sales of Squamous Cell Carcinoma drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan, Global
    Squamous Cell Carcinoma drugs sales forecast: Sales forecast for Squamous Cell Carcinoma drugs to 2023 by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Squamous Cell Carcinoma market share analysis: Find out the market shares of Squamous Cell Carcinoma drugs and outlook by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Did you know that we also offer Custom Research?

Global Non-Small Cell Lung Cancer Market and Competitive Landscape 2014-2018 & 2023

Retrieved on: 
Friday, October 26, 2018
Cancer, Lung cancer, Medicine, Health effects of tobacco, Small-cell carcinoma, Epidemiology of cancer, Savolitinib, PARAMOUNT trial

The "Global Non-Small Cell Lung Cancer Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Non-Small Cell Lung Cancer Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Non-Small Cell Lung Cancer Market and Competitive Landscape - 2018, provides comprehensive insights into Non-Small Cell Lung Cancer pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • The research is classified into following sections - Non-Small Cell Lung Cancer overview with definitions, symptoms, etiology, diagnosis, treatment options; Non-Small Cell Lung Cancer pipeline insights covering late stage clinical trials pipeline; Non-Small Cell Lung Cancer prevalence trends by countries; Non-Small Cell Lung Cancer market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Non-Small Cell Lung Cancer pipeline: Find out the drugs in clinical trials for Non-Small Cell Lung Cancer by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Non-Small Cell Lung Cancer epidemiology: Find out the prevalence of Non-Small Cell Lung Cancer by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2023
    Non-Small Cell Lung Cancer products: Identify key products marketed and prescribed for Non-Small Cell Lung Cancer by brand name, by molecule, by company, by branded / generic, by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Non-Small Cell Lung Cancer market size: Find out the market size for Non-Small Cell Lung Cancer drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2014
    Non-Small Cell Lung Cancer drug sales: Find out the sales of Non-Small Cell Lung Cancer drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan, Global
    Non-Small Cell Lung Cancer drugs sales forecast: Sales forecast for Non-Small Cell Lung Cancer drugs to 2023 by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Non-Small Cell Lung Cancer market share analysis: Find out the market shares of Non-Small Cell Lung Cancer drugs and outlook by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Did you know that we also offer Custom Research?